Horizon Therapeutics [HZNP] vs Pfizer [PFE] Detailed Stock Comparison

Horizon Therapeutics Plc

NASDAQ
Loading...

Pfizer Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Horizon Therapeutics Plc wins in 7 metrics, Pfizer Inc. wins in 10 metrics, with 0 ties. Pfizer Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Horizon Therapeutics Plc Pfizer Inc. Better
P/E Ratio (TTM) 61.86 19.61 Pfizer Inc.
Price-to-Book Ratio 5.01 1.75 Pfizer Inc.
Debt-to-Equity Ratio 0.48 77.96 Horizon Therapeutics Plc
PEG Ratio -16.29 -0.04 Pfizer Inc.
EV/EBITDA 24.08 8.01 Pfizer Inc.
Profit Margin (TTM) 74.64% 12.42% Horizon Therapeutics Plc
Operating Margin (TTM) 16.83% 23.95% Pfizer Inc.
EBITDA Margin (TTM) 16.83% 23.95% Pfizer Inc.
Return on Equity 10.28% 8.89% Horizon Therapeutics Plc
Return on Assets (TTM) 5.72% 5.68% Horizon Therapeutics Plc
Free Cash Flow (TTM) N/A $9.08B N/A
Dividend Yield N/A 6.71% N/A
1-Year Return -6.82% 6.81% Pfizer Inc.
Price-to-Sales Ratio (TTM) 7.34 2.42 Pfizer Inc.
Enterprise Value $26.84B $206.00B Pfizer Inc.
EV/Revenue Ratio 7.40 3.29 Pfizer Inc.
Gross Profit Margin (TTM) 76.72% 69.97% Horizon Therapeutics Plc
Revenue per Share (TTM) $16 $11 Horizon Therapeutics Plc
Earnings per Share (Diluted) $2.22 $1.36 Horizon Therapeutics Plc
Beta (Stock Volatility) N/A 0.39 N/A
Short % of Float N/A 2.33% N/A

Horizon Therapeutics Plc vs Pfizer Inc. Stock Performance Analysis

Loading Price Chart...

HZNP
PFE

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Horizon Therapeutics Plc0.00%N/AN/AN/AN/AN/A
Pfizer Inc.-0.80%1.48%2.65%-2.29%-1.63%3.26%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Horizon Therapeutics Plc-6.82%74.04%9.84%176.66%176.66%176.66%
Pfizer Inc.6.81%-34.57%-32.47%-19.28%36.37%17.90%

Performance & Financial Health Analysis: Horizon Therapeutics Plc vs Pfizer Inc.

MetricHZNPPFE
Market Information
Market Cap i$26.63B$153.59B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i19,134,20630,662,931
90 Day Avg. Volume i8,460,69536,790,755
Last Close$116.30$26.00
52 Week Range$116.30 - $116.34$23.11 - $28.75
% from 52W High-0.03%-9.57%
All-Time High$39.49 (Jul 20, 2015)$61.71 (Dec 20, 2021)
% from All-Time High194.50%-57.87%
Growth Metrics
Quarterly Revenue Growth0.14%-0.01%
Quarterly Earnings GrowthN/A-0.01%
Financial Health
Profit Margin (TTM) i0.75%0.12%
Operating Margin (TTM) i0.17%0.24%
Return on Equity (TTM) i0.10%0.09%
Debt to Equity (MRQ) i0.4877.96
Cash & Liquidity
Book Value per Share (MRQ)$23.22$15.21
Cash per Share (MRQ)N/A$2.39
Operating Cash Flow (TTM) i$1.33B$11.70B
Levered Free Cash Flow (TTM) i$1.81B$13.43B
Dividends
Last 12-Month Dividend Yield iN/A6.71%
Last 12-Month Dividend iN/A$1.72

Valuation & Enterprise Metrics Analysis: Horizon Therapeutics Plc vs Pfizer Inc.

MetricHZNP (Apr 30, 2025)PFE (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i61.8619.61
Forward P/E i20.559.48
PEG Ratio i-16.29-0.04
Price to Sales (TTM) i7.342.42
Price to Book (MRQ) i5.011.75
Market Capitalization
Market Capitalization i$26.63B$153.59B
Enterprise Value i$26.84B$206.00B
Enterprise Value Metrics
Enterprise to Revenue i7.403.29
Enterprise to EBITDA i24.088.01
Risk & Other Metrics
Beta iN/A0.39
Book Value per Share (MRQ) i$23.22$15.21

Financial Statements Comparison: Horizon Therapeutics Plc vs Pfizer Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricHZNPPFE (2025)
Revenue/Sales iN/A62.58B
Cost of Goods Sold iN/A16.07B
COGS % of Revenue i-25.7%
Gross Profit iN/A46.51B
Gross Margin i-74.3%
Research & Development iN/A10.44B
Operating Income (EBIT) iN/A17.41B
Operating Margin i-27.8%
EBITDA iN/A25.75B
EBITDA Margin i-41.1%
Pre-Tax Income iN/A7.52B
Pre-Tax Income % of Revenue i-12.0%
Income Tax iN/A-266.00M
Income Tax % of Revenue i--0.4%
Net Income (Profit) iN/A7.81B
Profit Margin i-12.5%

Balance Sheet & Liquidity Metrics

MetricHZNPPFE (2025)
Cash & Equivalents iN/A1.14B
Total Current Assets iN/A42.90B
Total Current Assets % of Revenue i-68.6%
Total Current Liabilities iN/A36.98B
Total Current Liabilities % of Revenue i-59.1%
Long-Term Debt iN/A60.81B
Long-Term Debt % of Revenue i-97.2%
Total Shareholders Equity iN/A86.78B
Retained Earnings iN/A114.61B
Retained Earnings % of Revenue i-183.1%
Property, Plant & Equipment iN/A0

Cash Flow Statement Comparison

MetricHZNPPFE (2025)
Operating Cash Flow iN/A6.43B
Operating Cash Flow % of Revenue i-10.3%
Capital Expenditures iN/A-2.63B
Free Cash Flow iN/A9.08B
FCF Margin i-14.5%
Debt Repayment iN/A-9.75B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricHZNPPFE
Shares Short iN/A132.47M
Short Ratio iN/A3.17
Short % of Float iN/A2.33%
Shares Outstanding i229.00M5.69B
Float Shares iN/A5.68B
% Held by Insiders iN/A0.10%
% Held by Institutions iN/A68.38%
% Held by Public iN/A31.52%

Dividend Analysis & Yield Comparison: Horizon Therapeutics Plc vs Pfizer Inc.

MetricHZNPPFE
Last 12-Month Dividend iN/A$1.72
Last 12-Month Dividend Yield iN/A6.71%
3-Year Avg Annual Dividend iN/A$1.69
3-Year Avg Dividend Yield iN/A1.54%
3-Year Total Dividends iN/A$5.06
Ex-Dividend DateN/AJan 23, 2026